This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
D. Aarsland , U. P. Mosimann and I. G. McKeith (2004). Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology, 17, 164–171.
D. Aarsland (2005). Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Journal of Clinical Psychiatry, 66, 633–637.
R. Ceravolo (2003). Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurological Sciences, 24, 162–163.
M. Firbank , S. J. Colloby , D. Burn , I. G. McKeith and J. T. O'Brien (2003). Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage, 20, 1309–1319.
M. F. Folstein , S. E. Folstein and P. R. McHugh (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
S. Gilman (2005). Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18 F]fluorodeoxyglucose and neuropsychological testing. Experimental Neurology, 191 (Suppl. 1), S95–S103.
H. Hanyu (2006a). Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 33, 248–253.
M. B. Imran (1999). Tc-99 m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. Journal of Neurology, Neurosurgery and Psychiatry, 66, 228–232.
K. Ishii (1998). Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology, 51, 125–130.
K. Ishii , M. Sasaki , S. Sakamoto , S. Yamaji , H. Kitagaki and E. Mori (1999a). Tc-99 m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer's disease: comparison of perfusion and metabolic patterns. Clinical Nuclear Medicine, 24, 572–575.
K. Ishii , S. Yamaji , H. Kitagaki , T. Imamura , N. Hirono and E. Mori (1999b). Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology, 53, 413–416.
P. M. Kemp , S. A. Hoffmann , L. Tossici-Bolt , J. S. Fleming and C. Holmes (2007). Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nuclear Medicine Communications, 28, 451–456.
K. Lobotesis (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology, 56, 643–649.
I. G. McKeith (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65, 1863–1872.
I. McKeith (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, 6, 305–313.
J. T. O'Brien (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925.
T. Oide (2003). Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Internal Medicine, 42, 686–690.
S. Shimizu , H. Hanyu , H. Kanetaka , T. Iwamoto , K. Koizumi and K. Abe (2005). Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dementia and Geriatric Cognitive Disorders, 20, 25–30.
Z. Walker (2007). Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of Neurology, Neurosurgery and Psychiatry, 78, 1176–1181.